Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.

Cancer journal (Sudbury, Mass.) - 1 Jan 2000

Cuneo Antonio, Cavazzini Francesco, Cavallari Maurizio, Foà Robin, Rigolin Gian Matteo

Abstract excerpt

ABSTRACT: In this article, we carry out an overview on the management options available for chronic lymphocytic leukemia (CLL) patients and discuss possible treatment decisions, taking into account the issue of sustainability and availability. Targeted agents have shown to be superior compared with chemoimmunotherapy (CIT) in terms of progression-free survival in high-risk CLL. In the majority of studies,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Immunotherapy
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Identifiers

PMID: 34398559
DOI: 10.1097/PPO.0000000000000531

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.PMID 34398559Read ↗

Cost-effectiveness of anti-CD20 monoclonal antibody associated with fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia in the Brazilian public health system (SUS)Semantic proximity Read ↗

Cost-effectiveness Analysis of Rituximab Associated With Fludarabine and Cyclophosphamide (R-FC) for the First-line Treatment of Chronic Lymphocytic Leukemia Under the Brazilian Public Health System (SUS).Semantic proximity Read ↗

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.Semantic proximity Read ↗

[Chronic lymphocytic leukemia : treatment concepts in transition].Semantic proximity Read ↗

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.Semantic proximity Read ↗

Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.Semantic proximity Read ↗

Optimizing frontline therapy of CLL based on clinical and biological factors.Semantic proximity Read ↗

Chronic lymphocytic leukemia treatment algorithm 2022.Semantic proximity Read ↗

Cost of illness and economic burden of chronic lymphocytic leukemiaSemantic proximity Read ↗

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.Semantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

Ibrutinib versus bendamustine plus rituximab for first-line treatment of older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.